The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz in antiretroviral-naïve patients through 7 years

Purpose of the study Study 903 is a Phase III trial with a 3-year, double-blind phase comparing tenofovir DF (TDF) to stavudine in combination with lamivudine (3TC) and efavirenz (EFV). In the study, TDF was associated with durable efficacy, better lipid profiles and less lipodystrophy. Study 903E is the ongoing open-label (OL) extension evaluating up to 10year safety and efficacy of a once-daily TDF+3TC+EFV regimen.